Equillium, Inc. (EQ)

Market Cap	16.83M
Revenue (ttm)	41.10M
Net Income (ttm)	-8.07M
Shares Out	35.61M
EPS (ttm)	-0.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	74,707
Open	0.4690
Previous Close	0.4374
Day's Range	0.4611 - 0.4700
52-Week Range	0.3600 - 1.8900
Beta	1.86
Analysts	Buy
Price Target	3.00 (+542.4%)
Earnings Date	May 8, 2025

About EQ

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and in phase 2 clinical trial for the treatment of ul...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 11, 2018
• Employees: 35
• Stock Exchange: NASDAQ
• Ticker Symbol: EQ
• Website: https://www.equilliumbio.com

Financial Performance

In 2024, Equillium's revenue was $41.10 million, an increase of 13.89% compared to the previous year's $36.08 million. Losses were -$8.07 million, -39.51% less than in 2023.

Analyst Forecast

According to 3 analysts, the average rating for EQ stock is "Buy." The 12-month stock price forecast is $3.0, which is an increase of 542.40% from the latest price.

Price Target

$3.0

(542.40% upside)

Analyst Consensus: Buy